I was 'slightly' reassured by the last paragraph... which still reports the data is expected second half of 2024 Calendar Year.
"Next Steps
ATL1102 is currently the subject of an ongoing international phase IIb clinical trial in Duchenne muscular dystrophy, with data anticipated in 2H CY2024."
Ann: ATL1102 DMD Phase IIA Final Data Published, page-6
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $102.2K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 341125 | 4 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |